Inhibrx Biosciences

INBXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.301 B

$88.66 +3.35%

Close of 7 Aug 2026

Revenue

$1.30M

#3482 by revenue

Earnings

-$140.1M

Loss-making

Shares outstanding

14,607,036

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#42Monte Rosa TherapeuticsGLUE$1.34B
#43NovavaxNVAX$1.31B
#44Inhibrx BiosciencesINBX$1.30B
#45ImmaticsIMTX$1.29B
#46Vor BiopharmaVOR$1.28B

Where these numbers come from

Share counts and financials for Inhibrx Biosciences are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.